Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 88,399 |
|
|||||
| News | - | ||||||
| Day High | 12.04 | Low High |
|||||
| Day Low | 12.00 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oculis Holding AG | OCS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.07 | 0.59% | 12.02 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 12.01 | 12.00 | 12.04 | 12.02 | 11.95 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 372 | 88,399 | $ 12.01 | $ 1,061,804 | - | 9.05 - 14.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 155 | $ 12.02 | USD |
Oculis Holding AG Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 440.53M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oculis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OCS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 11.75 | 12.45 | 11.72 | 11.95 | 155,957 | 0.27 | 2.30% |
| 1 Month | 12.07 | 12.45 | 10.55 | 11.74 | 75,509 | -0.05 | -0.41% |
| 3 Months | 12.86 | 13.8499 | 10.55 | 11.91 | 38,293 | -0.84 | -6.53% |
| 6 Months | 10.00 | 14.465 | 9.05 | 11.74 | 36,579 | 2.02 | 20.20% |
| 1 Year | 11.13 | 14.50 | 9.05 | 11.81 | 28,237 | 0.89 | 8.00% |
| 3 Years | 10.95 | 14.50 | 6.26 | 11.39 | 28,278 | 1.07 | 9.77% |
| 5 Years | 10.95 | 14.50 | 6.26 | 11.39 | 28,278 | 1.07 | 9.77% |
Oculis Description
| Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. |
